Clozapine (Clozaril) is reserved for severe and refractory schizophrenia because:

Clozapine (Clozaril) is an atypical antipsychotic used for treatment-resistant schizophrenia when other antipsychotics have failed. It is highly effective in reducing psychotic symptoms, especially in refractory cases, but its use is limited by serious and potentially life-threatening adverse effects. Because of these risks, it requires strict hematologic monitoring and is only used under specialized prescribing programs. Its safety profile is the main reason it is not first-line therapy. Rationale: A. Clozapine is not reserved for refractory schizophrenia due to cost, even though it may be more expensive than other antipsychotics. The primary limitation to its use is safety, not financial factors. Clinical decision-making is based on risk of serious adverse effects rather than medication cost alone. B. Clozapine does not primarily mask hypoglycemia symptoms. While some antipsychotics can affect metabolic regulation and increase the risk of diabetes, masking hypoglycemia is not a key reason for restricted use of Clozapine (Clozaril). The major concern is hematologic toxicity rather than glucose symptom masking. C. QTc prolongation can occur with some antipsychotics, but it is not the most significant or defining risk that restricts use of Clozapine (Clozaril). While cardiac monitoring is important, other agents such as ziprasidone have more prominent QTc concerns. Clozapine’s restriction is primarily driven by hematologic toxicity. D. Clozapine carries a risk of severe and potentially fatal agranulocytosis, which is a profound decrease in white blood cells that can lead to life-threatening infections. Because of this risk, patients require mandatory regular absolute neutrophil count (ANC) monitoring under strict protocols. This serious hematologic adverse effect is the main reason Clozapine (Clozaril) is reserved for treatment-resistant schizophrenia.